FGF-19 Double Nickase Plasmid (h): sc-401725-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- FGF-19 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- FGF-19 Double Nickase Plasmid (h) and FGF-19 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting FGF19. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: FGF-19 Antibody (H-12): sc-390621
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
FGF-19 Double Nickase Plasmid (h) | sc-401725-NIC | 20 µg | $410.00 | |||
FGF-19 Double Nickase Plasmid (h2) | sc-401725-NIC-2 | 20 µg | $410.00 |
FGF19 encodes fibroblast growth factor 19 (FGF-19), an endocrine FGF that signals primarily through FGFR4 in complex with the co-receptor β-Klotho to regulate bile acid synthesis, lipid metabolism, and energy homeostasis. In hepatocytes, FGF-19 suppresses CYP7A1 expression downstream of FXR-driven intestinal feedback, integrating nutrient sensing with metabolic gene programs. This signaling axis interfaces with MAPK/ERK and PI3K/AKT pathways, influencing proliferation and metabolic adaptation. Dysregulated FGF19 expression or signaling has been associated with metabolic disorders and oncogenic phenotypes in tissues where FGFR4–β-Klotho is active, supporting its study in liver biology and cancer-related signaling networks.
FGF-19 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the FGF19 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within FGF19. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt FGF19 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of FGF19-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.